Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
23.21B
Market cap23.21B
Price-Earnings ratio
34.07
Price-Earnings ratio34.07
Dividend yield
Dividend yield
Average volume
2.09M
Average volume2.09M
High today
$152.78
High today$152.78
Low today
$149.99
Low today$149.99
Open price
$151.55
Open price$151.55
Volume
440.78K
Volume440.78K
52 Week high
$155.53
52 Week high$155.53
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $151.90, with a market capitalization of 23.21B. The stock trades at a price-to-earnings (P/E) ratio of 34.07.

During the trading session on 2026-01-28, Illumina(ILMN) shares reached a daily high of $152.78 and a low of $149.99. At a current price of $151.90, the stock is +1.3% higher than the low and still -0.6% under the high.

Trading volume for Illumina(ILMN) stock has reached 440.78K, versus its average volume of 2.09M.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

ILMN News

TipRanks 2d
Illumina price target raised to $170 from $144 at Guggenheim

Guggenheim analyst Subbu Nambi raised the firm’s price target on Illumina (ILMN) to $170 from $144 and keeps a Buy rating on the shares. The firm adjusted model...

Simply Wall St 4d
Illumina Valuation Check After CMS Reimbursement Milestone In Precision Oncology

The key trigger for Illumina (ILMN) right now is the CMS decision to reimburse its FDA approved TruSight Oncology Comprehensive test, which creates a national p...

Illumina Valuation Check After CMS Reimbursement Milestone In Precision Oncology
Simply Wall St 6d
Why Illumina Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement

Earlier in January 2026, Illumina announced that the Centers for Medicare and Medicaid Services granted reimbursement for its FDA-approved TruSight Oncology Com...

Why Illumina Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement

Analyst ratings

43%

of 23 ratings
Buy
39.1%
Hold
43.5%
Sell
17.4%

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.